Targetable ABL-fusions (14.1%; ABL1(ABL), ABL2, CSF1R and PDGFRB), and EPOR rearrangements or JAK2 fusions (8.8%) have been identified in Ph-like ALL patients by RNA-sequencing [15,107]. This evidence concerns the gene CSF1R and acute lymphoblastic leukemia.